Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
2.

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.

van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team.

Ann Rheum Dis. 2018 Jan 17. pii: annrheumdis-2017-212478. doi: 10.1136/annrheumdis-2017-212478. [Epub ahead of print]

PMID:
29343509
3.

Adiposity in Juvenile Psoriatic Arthritis.

Samad A, Stoll ML, Lavi I, Hsu JJ, Strand V, Robinson TN, Mellins ED, Zisman D; for the CARRA Legacy Registry Investigators .

J Rheumatol. 2017 Dec 15. pii: jrheum.170598. doi: 10.3899/jrheum.170598. [Epub ahead of print]

PMID:
29247150
4.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2017 Nov 28. doi: 10.1002/art.40391. [Epub ahead of print]

PMID:
29193765
5.

Discordant patient-physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis.

Karpouzas GA, Ramadan SN, Cost CE, Draper TL, Hernandez E, Strand V, Ormseth SR.

RMD Open. 2017 Oct 25;3(2):e000551. doi: 10.1136/rmdopen-2017-000551. eCollection 2017.

6.

Trial Characteristics as Contextual Factors when Evaluating Targeted Therapies in Patients with Psoriatic Disease: A Meta-Epidemiological Study.

Ballegaard C, Jørgensen TS, Skougaard M, Strand V, Mease PJ, Kristensen LE, Dreyer L, Gottlieb A, de Wit M, Christensen R, Tarp S.

Arthritis Care Res (Hoboken). 2017 Oct 26. doi: 10.1002/acr.23455. [Epub ahead of print]

PMID:
29073353
7.

Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study.

Tamm S, Cervenka S, Forsberg A, Estelius J, Grunewald J, Gyllfors P, Karshikoff B, Kosek E, Lampa J, Lensmar C, Strand V, Åkerstedt T, Halldin C, Ingvar M, Olgart Höglund C, Lekander M.

Brain Behav Immun. 2018 Feb;68:146-157. doi: 10.1016/j.bbi.2017.10.013. Epub 2017 Oct 18.

8.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2017 Sep 9. pii: S0049-0172(17)30182-8. doi: 10.1016/j.semarthrit.2017.09.002. [Epub ahead of print] Review.

PMID:
29037523
9.

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G.

RMD Open. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496. eCollection 2017.

10.

Patient Burden of Axial Spondyloarthritis.

Strand V, Singh JA.

J Clin Rheumatol. 2017 Oct;23(7):383-391. doi: 10.1097/RHU.0000000000000589.

11.

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.

Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J.

Rheumatol Ther. 2017 Dec;4(2):489-502. doi: 10.1007/s40744-017-0078-y. Epub 2017 Aug 22.

12.

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, Beukelman T, Brunner HI, Creek EL, Harris JG, Horton DB, Lovell DJ, Mannion ML, Olson JC, Rahimi H, Gallo MC, Calandra S, Ravelli A, Ringold S, Shenoi S, Stinson J, Toupin-April K, Strand V, Bingham CO 3rd.

J Rheumatol. 2017 Dec;44(12):1884-1888. doi: 10.3899/jrheum.161389. Epub 2017 Aug 15.

PMID:
28811355
13.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2017 Aug 12. pii: S1521-6616(17)30543-0. doi: 10.1016/j.clim.2017.08.009. [Epub ahead of print]

PMID:
28811201
14.

Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.

Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO 3rd, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2017 Oct;44(10):1551-1559. doi: 10.3899/jrheum.161273. Epub 2017 Aug 1.

PMID:
28765256
15.

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.

Rheumatol Ther. 2017 Dec;4(2):349-362. doi: 10.1007/s40744-017-0070-6. Epub 2017 Jul 31.

16.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2017 Jul 26. pii: annrheumdis-2017-212004. doi: 10.1136/annrheumdis-2017-212004. [Epub ahead of print] No abstract available.

PMID:
28747326
17.

Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report.

Zamora NV, Christensen R, Goel N, Klokker L, Lopez-Olivo MA, Kristensen LE, Carmona L, Strand V, Curtis JR, Suarez-Almazor ME.

J Rheumatol. 2017 Dec;44(12):1894-1898. doi: 10.3899/jrheum.161108. Epub 2017 Jun 15.

PMID:
28620065
18.

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8. Review.

19.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

PMID:
28461531
20.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.

RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017.

22.

Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.

Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.

J Med Econ. 2017 Jul;20(7):703-714. doi: 10.1080/13696998.2017.1307205. Epub 2017 Apr 5.

PMID:
28294642
23.
24.

Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease.

Strand V, Singh JA.

Mayo Clin Proc. 2017 Apr;92(4):555-564. doi: 10.1016/j.mayocp.2016.12.008. Epub 2017 Feb 21. Review.

25.

Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial.

Strand V, Bergman M, Singh JA, Gibofsky A, Kivitz A, Young C.

Clin Rheumatol. 2017 Jun;36(6):1357-1367. doi: 10.1007/s10067-017-3569-x. Epub 2017 Feb 13.

PMID:
28194525
26.

The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes.

Zisman D, Gladman DD, Stoll ML, Strand V, Lavi I, Hsu JJ, Mellins ED; CARRA Legacy Registry Investigators.

J Rheumatol. 2017 Mar;44(3):342-351. doi: 10.3899/jrheum.160717. Epub 2017 Feb 1.

PMID:
28148698
27.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1.

28.

Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study.

Kristensen LE, Jørgensen TS, Christensen R, Gudbergsen H, Dreyer L, Ballegaard C, Jacobsson LTH, Strand V, Mease PJ, Kjellberg J.

Ann Rheum Dis. 2017 Sep;76(9):1495-1501. doi: 10.1136/annrheumdis-2016-210579. Epub 2017 Jan 30.

PMID:
28137915
29.

The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.

Strand V, Girolomoni G, Schiestl M, Ernst Mayer R, Friccius-Quecke H, McCamish M.

Curr Med Res Opin. 2017 Jun;33(6):993-1003. doi: 10.1080/03007995.2017.1288612. Epub 2017 Feb 7. Review.

PMID:
28133979
30.

From mechanism to therapies in systemic lupus erythematosus.

Paley MA, Strand V, Kim AH.

Curr Opin Rheumatol. 2017 Mar;29(2):178-186. doi: 10.1097/BOR.0000000000000369. Review.

PMID:
28118202
31.

Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.

Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, Wang L.

Rheumatology (Oxford). 2017 Jan;56(1):46-57. doi: 10.1093/rheumatology/kew329. Epub 2016 Oct 22.

PMID:
28028154
32.

Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials.

Peterfy C, Strand V, Tian L, Østergaard M, Lu Y, DiCarlo J, Countryman P, Deodhar A, Landewé R, Ranganath VK, Troum O, Conaghan PG.

Ann Rheum Dis. 2017 Jun;76(6):992-997. doi: 10.1136/annrheumdis-2016-210311. Epub 2016 Dec 14.

PMID:
27974302
33.

Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al.

Curtis JR, Wright GC, Strand V, Davis CS, Hitraya E, Sasso EH.

Arthritis Rheumatol. 2017 Apr;69(4):863-865. doi: 10.1002/art.39981. Epub 2017 Mar 3. No abstract available.

PMID:
27813312
34.

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.

Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Gruben D, Wilkinson B, Krishnaswami S, Wallenstein G.

RMD Open. 2016 Sep 28;2(2):e000308. eCollection 2016.

35.

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.

Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Rheumatol Ther. 2016 Dec;3(2):305-322. Epub 2016 Sep 15.

36.

Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.

Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Woodworth T, Leong AL, Goel N, Boers M, Brooks PM, Simon LS, Christensen R.

J Rheumatol. 2017 Dec;44(12):1916-1919. doi: 10.3899/jrheum.161105. Epub 2016 Oct 15.

PMID:
27744393
37.

Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT).

de Wit M, Kirwan JR, Tugwell P, Beaton D, Boers M, Brooks P, Collins S, Conaghan PG, D'Agostino MA, Hofstetter C, Hughes R, Leong A, Lyddiatt A, March L, May J, Montie P, Richards P, Simon LS, Singh JA, Strand V, Voshaar M, Bingham CO 3rd, Gossec L.

Patient. 2017 Apr;10(2):141-152. doi: 10.1007/s40271-016-0198-4.

38.

Importance of 'meeting of the minds': patient-reported outcomes and MRI.

Ranganath VK, Strand V.

Ann Rheum Dis. 2017 Mar;76(3):473-475. doi: 10.1136/annrheumdis-2016-210058. Epub 2016 Sep 29. No abstract available.

PMID:
27689734
39.

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.

Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S.

Ann Rheum Dis. 2017 Mar;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668. Epub 2016 Sep 26.

40.

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis.

Scott IC, Ibrahim F, Lewis CM, Scott DL, Strand V.

RMD Open. 2016 Aug 26;2(2):e000270. doi: 10.1136/rmdopen-2016-000270. eCollection 2016.

41.

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A.

Ann Rheum Dis. 2017 Apr;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242. Epub 2016 Sep 9.

42.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, van Hoogstraten H, Bayliss M, Fan C, Huizinga T, Genovese MC.

Arthritis Res Ther. 2016 Sep 6;18:198. doi: 10.1186/s13075-016-1096-9.

43.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3.

44.

Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.

Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV.

Arthritis Care Res (Hoboken). 2017 Apr;69(4):592-598. doi: 10.1002/acr.23004.

45.

A critical review of clinical trials in systemic lupus erythematosus.

Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R.

Lupus. 2016 Sep;25(10):1122-40. doi: 10.1177/0961203316652492. Review.

46.

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.

Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J, Marren A.

Drug Saf. 2016 Aug;39(8):755-62. doi: 10.1007/s40264-016-0431-z.

48.

Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.

Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV.

Arthritis Res Ther. 2016 May 21;18(1):114. doi: 10.1186/s13075-016-1004-3.

49.

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis.

Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E.

RMD Open. 2016 Apr 26;2(1):e000232. doi: 10.1136/rmdopen-2015-000232. eCollection 2016.

50.

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).

Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S; FUTURE 1 study group.

Ann Rheum Dis. 2017 Jan;76(1):203-207. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.

PMID:
27169431

Supplemental Content

Loading ...
Support Center